2.4 USD
-0.09 (-3.61%)
Taking everything into account, WHWK scores 4 out of 10 in our fundamental rating. WHWK was compared to 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for WHWK as it has an excellent financial health rating, but there are worries on the profitability. WHWK does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
WHWK had negative earnings in the past year.
WHWK had a negative operating cash flow in the past year.
In the past 5 years WHWK always reported negative net income.
In the past 5 years WHWK always reported negative operating cash flow.
1.2 Ratios
WHWK has a Return On Assets of -9.35%. This is amongst the best in the industry. WHWK outperforms 84.18% of its industry peers.
Looking at the Return On Equity, with a value of -9.94%, WHWK belongs to the top of the industry, outperforming 87.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.35% | ||
| ROE | -9.94% | ||
| ROIC | N/A |
ROA(3y)-57.7%
ROA(5y)-50.49%
ROE(3y)-74.03%
ROE(5y)-62.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 89.22%, WHWK belongs to the best of the industry, outperforming 90.96% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for WHWK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.22% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
WHWK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, WHWK has more shares outstanding
Compared to 5 years ago, WHWK has more shares outstanding
There is no outstanding debt for WHWK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
WHWK has an Altman-Z score of 3.44. This indicates that WHWK is financially healthy and has little risk of bankruptcy at the moment.
WHWK's Altman-Z score of 3.44 is fine compared to the rest of the industry. WHWK outperforms 69.30% of its industry peers.
There is no outstanding debt for WHWK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.44 |
ROIC/WACCN/A
WACC8.78%
2.3 Liquidity
A Current Ratio of 16.76 indicates that WHWK has no problem at all paying its short term obligations.
WHWK has a better Current ratio (16.76) than 93.22% of its industry peers.
A Quick Ratio of 16.76 indicates that WHWK has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 16.76, WHWK belongs to the top of the industry, outperforming 93.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.76 | ||
| Quick Ratio | 16.76 |
3. Growth
3.1 Past
WHWK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.65%, which is quite good.
WHWK shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -42.62%.
WHWK shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 185.21% yearly.
EPS 1Y (TTM)9.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.48%
Revenue 1Y (TTM)-42.62%
Revenue growth 3Y185.21%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
WHWK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.55% yearly.
Based on estimates for the next years, WHWK will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y88.06%
EPS Next 2Y18.43%
EPS Next 3Y10.55%
EPS Next 5YN/A
Revenue Next Year-72.5%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for WHWK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for WHWK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.43%
EPS Next 3Y10.55%
5. Dividend
5.1 Amount
No dividends for WHWK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:WHWK (12/8/2025, 2:33:08 PM)
2.4
-0.09 (-3.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners58.42%
Inst Owner ChangeN/A
Ins Owners12.42%
Ins Owner ChangeN/A
Market Cap113.11M
Revenue(TTM)14.38M
Net Income(TTM)-15.62M
Analysts47.5
Price Target2.04 (-15%)
Short Float %2.64%
Short Ratio0.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-366.68%
Min EPS beat(2)-482.33%
Max EPS beat(2)-251.03%
EPS beat(4)1
Avg EPS beat(4)-227.7%
Min EPS beat(4)-482.33%
Max EPS beat(4)21.14%
EPS beat(8)4
Avg EPS beat(8)-110.08%
EPS beat(12)7
Avg EPS beat(12)-69.58%
EPS beat(16)10
Avg EPS beat(16)-50.39%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)85.99%
EPS NQ rev (3m)89.41%
EPS NY rev (1m)63.82%
EPS NY rev (3m)73.68%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.27%
Revenue NY rev (3m)-0.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.86 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.72 | ||
| P/tB | 0.72 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.06
EYN/A
EPS(NY)-1.4
Fwd EYN/A
FCF(TTM)-2.04
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS0.31
BVpS3.33
TBVpS3.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.35% | ||
| ROE | -9.94% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.22% | ||
| FCFM | N/A |
ROA(3y)-57.7%
ROA(5y)-50.49%
ROE(3y)-74.03%
ROE(5y)-62.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 590.4% | ||
| Cap/Sales | 5.13% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 16.76 | ||
| Quick Ratio | 16.76 | ||
| Altman-Z | 3.44 |
F-Score4
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)1160.76%
Cap/Depr(5y)712.22%
Cap/Sales(3y)8.52%
Cap/Sales(5y)6.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.48%
EPS Next Y88.06%
EPS Next 2Y18.43%
EPS Next 3Y10.55%
EPS Next 5YN/A
Revenue 1Y (TTM)-42.62%
Revenue growth 3Y185.21%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-72.5%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-70.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.31%
OCF growth 3YN/A
OCF growth 5YN/A
WHITEHAWK THERAPEUTICS INC / WHWK FAQ
What is the fundamental rating for WHWK stock?
ChartMill assigns a fundamental rating of 4 / 10 to WHWK.
Can you provide the valuation status for WHITEHAWK THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to WHITEHAWK THERAPEUTICS INC (WHWK). This can be considered as Overvalued.
How profitable is WHITEHAWK THERAPEUTICS INC (WHWK) stock?
WHITEHAWK THERAPEUTICS INC (WHWK) has a profitability rating of 2 / 10.
What is the earnings growth outlook for WHITEHAWK THERAPEUTICS INC?
The Earnings per Share (EPS) of WHITEHAWK THERAPEUTICS INC (WHWK) is expected to grow by 88.06% in the next year.
Is the dividend of WHITEHAWK THERAPEUTICS INC sustainable?
The dividend rating of WHITEHAWK THERAPEUTICS INC (WHWK) is 0 / 10 and the dividend payout ratio is 0%.